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Abstract
Objective: Different findings indicate that CYP2C plays a clinical 
role in determining interindividual and interethnic differences 
in drug effectiveness. The ethnic differences in the frequency of 
CYP2C19 mutant alleles continue to be a significant study topic. 
The aim of the present study was to assess the frequency of allelic 
variants of CYP2C19 in Turkman ethnic groups and compare them 
with the frequencies in other ethnic populations.
Methods: The study group included 140 unrelated healthy ethnic 
Turkman subject referred to the Health Center. Genotyping of 
CYP2C19 alleles (CYP2C19*1, CYP2C19*2, and CYP2C19*3 
alleles) was carried out by Polymerase Chain Reaction-Restriction 
Fragment Length Polymorphism technique
Results: The allele frequency of CYP2C19*1, CYP2C19*2 
and CYP2C19*3 were 56.43%, 23.57% and 20%, respectively. 
The result also showed that 39.7% of subjects expressed the 
CYP2C19*1/*1 genotype. While 42.1%, 9.3%, 9.3% and 1.4% 
expressed CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2 
and CYP2C19*3/*3 genotypes, respectively. The genotype 
CYP2C19*2/*3 was not expressed in this study population. The 
findings suggested that 10% of subjects were poor metabolizers by 
expressing CYP2C19*2/*2 and CYP2C19*3/*3 genotypes. Fifty 
one percent of subjects were intermediate metabolizers having 
CYP2C19*1/*2, CYP2C19*2/*3 and CYP2C19*1/*3 genotypes 
and 37.86% were found to be extensive metabolizers expressing 
CYP2C19*1/*1 genotype. The frequency of intermediate 
metabolizers genotype was high (51%) in Turkman ethnic groups.
Conclusion: This study showed that the determined allelic variants 
of CYP2C19 (CYP2C19*2 and CYP2C19*3 mutations) in 
Turkman ethnic group are comparable to other populations. These 
findings could be useful for the clinicians in different country to 
determine optimal dosage and effectiveness of drugs metabolized 
by this polymorphic enzyme.
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Introduction
There are at least four isoforms of human CYP2C subfamily 
in mankind. The main forms are principally 2C8, 2C9, 2C18 
and 2C19. Their related genes are located on chromosome 10.1,2 
It has been shown that drug metabolism is directly related to 
genetic polymorphism and gene mutations manipulate the enzyme 
activities responsible for the drugs metabolism. Such enzyme 
activity modulation can present itself in three scenario of high, 
low and zero activities.3-5 From drug related genetic pattern, the 
human gene are sub-grouped into few phenotypes of poor (or slow) 
metabolizers (PM), intermediate metabolizers (IM), extensive (or 
rapid) metabolizers (EM), and ultrarapid metabolizers (UM).6 
There are various reports of drugs which adversely affect human 
metabolism, resulting either from drug toxicity or long-lasting 
therapeutic effect of some drugs even consumption at therapeutic 
dosage in poor or slow metabolizer phenotypes. The ultra rapid 
metabolizer phenotype probably does not demonstrate the related 
therapeutic effect and this may be the reason why some drugs do 
not produce any therapeutic effect even in genetically susceptible 
subjects. This manifestation of specific phenotypes is related to 
the pharmocogeneticity of particular polymorphism of poor or 
slow, extensive or rapid and ultra-rapid metabolizer. It has been 
shown that about 3% of Caucasians express the poor metabolizer 
phenotypes S-mephenytoin, however literature review in this 
regards shows slight differences.7,8 Other studies indicated that 
East Asian subjects express the poor metabolizer phenotypes 
at  higher frequency. Some researchers have indicated that 18-
23% of Japanese,9,10 15-17% of Chinese11,12 and 12-16% Koreans 
express the poor metabolizer phenotype.13,14 The same index for 
Black African was reported to be 4-7%.15 Reports suggest that 
the poor metabolizer phenotype is an autosomal recessive trait 
which is inherited.8 Same reports have considered CYP2C19*2 
and CYP2C19*3 to be the dominant poor metabolizer phenotype 
for malfunction of CYP2C19 alleles.16,17 Among East Asians, 
CYP2C19*2 is the major allele and it dominates about 75% of the 
defective alleles.16 These allele defections for Caucasians account for 
93% of population.18 CYP2C19*3 is the phenotype which comprises 
approximately 25% of the defective gene among East Asians which 
was initially found in a Japanese poor metabolizer population.17 But 
it was discovered that the above mentioned phenotype is significantly 
rare among non-East Asian sub-population.19 The incidence of 
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the poor metabolizer phenotype in European whites,7 and the 
residents of Vanuatu Island as well as Melanesia subjects,20 at a rate 
of 3-5% and 70%, respectively. The incidence of CYP2C19*2 and 
CYP2C19*3 alleles among north Indian subjects was reported to be 
as 29.7% and 0.00%, respectively.21 In an other study, the frequency 
of CYP2C19*2 and CYP2C19*3 alleles among South Indian of 
Tamil, Telgu, Kannada, and Malayalam backgrounds were reported 
to be 35% and 1%, respectively.22 The narrow therapeutic index of 
some drugs in particular are important safety in determining the 
drug metabolic capacity indications of some individual by applying 
the necessary phenotype and genotype standards to provide a safe 
guard for susceptible subjects. The aim of this study was to assess 
the distribution of CYP2C19 allele and genotypic variants among 
the Turkman ethnic group in comparison with other populations.
Methods
The study group included 140 unrelated healthy subjects of 
Turkman origin (people who speak Turkman as a native language 
and population inbreeding people) who were referred to the Health 
Center in Gonbadkavoos (located in North Eastern Iran, South 
East of the Caspian Sea). This present study, set to establish the 
prevalence of CYP2C19 variants in a sample of Turkman ethnic 
group and compare the collected data with other populations. 
Ethical approval was obtained from the ethics committee of 
Golestan University of Medical Sciences and informed consent was 
obtained from all participants.
Five milliliters of venous blood was sampled from each subject 
and collected into EDTA tubes. Extraction of DNA from peripheral 
white blood cells was done by salting out method.23 DNA extract 
was dissolved in sterilized distilled water and samples were kept in 
-20oC until analysis by polymerase chain reaction (PCR).
Genotyping of CYP2C19 alleles (CYP2C19*1, CYP2C19*2, 
and CYP2C19*3 alleles) was carried out by Polymerase Chain 
Reaction (PCR)-Restriction Fragment Length Polymorphism 
(RFLP) technique.24 PCR was done in 25 microliter mixture 
containing PCR buffer 10 mM Tris–HCl, pH 9, 1.5 mM MgCl2 
(Fermentase, Burlington; Canada), 50 mM KCl (Fermentase, 
Burlington; Canada), 10 mM deoxyribonucleotide triphosphate 
(dNTP) mix, 5 U/μl Taq polymerase (Fermentase, Burlington; 
Canada), 5 pM of each primer (Bioneer; Korea), 500 ng DNA 
(Genomic; Korea) and sterile distillated water. PCR was carried 
out in a genetix CG palm-thermocycler (New Delhi; India). 
PCR products (10μl) were digested with restriction enzymes 
(Fermentase; Burlington; Canada), (SmaI for CYP2C19*2 and 
BamHI for CYP2C19*3) at 30oC and 37oC for 16 hrs for compelte 
digestion, respectively. Primers amplification was done as described 
by De Morais et al.17 The DNA fragments were electrophoresed 
(Apelex, France) on a 2% (for CYP2C19*3) and 3% (for 
CYP2C19*3) agarose gel and stained with Ethidium bromide. 
Bands were detected by a short wavelength UV transluminator, 
photographed using a Polaroid Gel Camera with Polaroid black 
and white film. The CYP2C19*2 mutation was detected using 
sense primer 5'-AATTACAACCAGAGCTTGGC-3' and 
antisense primer 5'-TATCACTTTCCATAAAAGCAAG-3'. 
The detection of CYP2C19*3 was carried out using sense primer 
5'-AAATTGTTTCCAATCATTTAGCT-3' and antisense 
primer 5'-ACTTCAGGGCTTGGTCAATA-3'. The PCR 
amplification conditions for CYP2C9*2 and CYP2C9*3 were as 
follow: Initial denaturation, Number of cycle(s), Denaturation, 
Extention and Final extention step, which were 94oC, 300 sec.; 37; 
94oC, 60 sec.; 72oC, 30 sec. and 72oC, 300 sec., respectively. The 
annealing temperature and time for CYP2C9*2 and CYP2C9*3 
were 55oC, 30 sec. and 52oC, 45 sec., respectively. The Products of 
PCR before and after restriction enzyme digestion for CYP2C9*2 
and CYP2C9*3 genotypes are summarized in Fig. 1 and 2, 
respectively.
Figure 1: PCR-restriction enzyme (SmaI digestion) fragmentation 
patterns on the agarose gel is stained by ethidium bromide for 
CYP2C19*2 from subjects representing *1/*1, *1/*2, *1/*2, and 
*1/*1 genotypes (From 2 to 5 wells, left to right on the agarose 
gel). DNA ladder was loaded in well 1 and the sizes of the PCR-
restriction fragments were loaded in well 6.
Figure 2: PCR-restriction enzyme (BamHI digestion) 
fragmentation patterns on agarose gel is stained by ethidium 
bromide for CYP2C19*3 from subjects representing *1/*1, *1/*3, 
*1/*3, and *1/*1 genotypes (From 2 to 5 wells, left to right on the 
agarose gel). DNA ladder was loaded in well 1 and the sizes of the 
PCR-restriction fragments were loaded in well 6.
Statistical analysis was done to evaluate allele frequencies of 
CYP2C19 in Turkman subjects alongside other ethnic groups. 
The 95% confidence intervals (95% CI) for frequency of the variant 
alleles of each gene were determined. The observed genotype 
frequencies of CYP2C19 were observe and compared with expected 
frequencies according to the Hardy–Weinberg law. Differences 
in allele frequencies and PM genotype frequencies between the 
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Turkman ethnic group and other populations from various area 
swere measured by Fisher exact test. Data was analysed using SPSS 
version 16.0. and statistical significance was considered at p<0.05.
Results
The data revealed mean ages of the participants to be 29.73±9.11 
years old. Allele and genotype frequencies of CYP2C19 gene 
among the Turkman ethnic group are shown in Tables 1 and 2. 
The allele frequency of CYP2C19*1 (Wild type), CYP2C19*2 and 
CYP2C19*3 were 56.43% (95% CI: 48.15-64.36), 23.57% (95% 
CI: 17.31-31.25) and 20% (95% CI: 14.22-27.36), respectively. 
CYP2C19*1 was the most frequently (56.43%) determined allele 
in Turkman ethnic groups. The observed frequencies of CYP2C19 
genotypes in Turkman ethnic group were found to be in the 
Hardy-Weinberg equilibrium (Table 2). The results showed that 
39.7% of subjects expressed the CYP2C19*1/*1 genotype (95% 
CI: 30.25-46.11). While 59 (42.1%), 13 (9.3%), 13 (9.3%) and 2 
(1.4%) subjects expressed the CYP2C19*1/*2 (95% CI: 34.28-
50.42), CYP2C19*1/*3 (95% CI: 5.51-15.24), CYP2C19*2/*2 
(95% CI: 5.51-15.24) and CYP2C19*3/*3 (95% CI: 0.3-5) 
genotypes, respectively. There was no expression CYP2C19*2/*3 
(0%) genotype. Out of the alleles, CYP2C19*1/*2 (42.1%) was 
the most frequently observed mutant allele. Table 3 shows the 
prevalence of the predicted phenotypes of CYP2C19, which were 
as follow: 10.7% of subjects were PM carrying the CYP2C19*2/*2 
and CYP2C19*3/*3 genotypes (95% CI: 5.5-15). Fifty one percent 
of subjects were IM carrying the CYP2C19*1/*2, CYP2C19*2/*3 
and CYP2C19*1/*3 genotypes (95% CI: 43-60). Which 37.86% 
were found to be EM expressing the CYP2C19*1/*1 genotype 
(95% CI: 29.72-45.99). IM genotype frequency was high (51%) in 
the Turkman ethnic group.
Table 1: Allele frequencies of CYP2C19 gene among Turkman 
ethnic groups (n = 140).
Variant allele n Frequency (%) 95% CI
CYP2C19*1 79 56.43 48.15-64.36
CYP2C19*2 33 23.57 17.31-31.25
CYP2C19*3 28 20 14.22-27.36
Table 2: Genotype frequencies of CYP2C19 gene among Turkman 
ethnic groups (n = 140).
Genotype n Observed 
frequency %
Expected
frequency % by
Hardy–Weinberg 
law
CYP2C19*1/*1 53 37.9(30.25-46.11) 40.41
CYP2C19*1/*2 59 42.1(34.28-50.42) 38.6
CYP2C19*1/*3 13 9.3(5.51-15.24) 7.72
CYP2C19*2/*2 13 9.3(5.51-15.24) 9.22
CYP2C19*2/*3 - 0(-) 3.69
CYP2C19*3/*3 2 1.4(0.3-5) 0.37
Table 3: Prevalence of CYP2C19 predicted phenotypes in Turkman 
ethnic groups (n = 140) [χ2 test, p>0.05].
Genotype predicted 
phenotype
Frequency 
(%)
95% CI
CYP2C19*1/*1 EM 37.86 29.72-45.99
CYP2C19*1/*2, 
CYP2C19*1/*3 and 
CYP2C19*2/*3
IM 51 43-60
CYP2C19*2/*2 and 
CYP2C19*3/*3
PM 10.7 5.5-15
EM: Extensive metabolizers, IM: Intermediate metabolizers, PM: poor 
metabolizers.
Discussion
The Turkman ethnic group is a unique population in Iran, due to 
their population inbreeding, these people were considered to be 
particularly important in investigating the allele frequencies and 
genotype distributions of some variants of a pharmacogenetic 
interest. This is the first study based on the CYP2C19 genotype 
distribution in this ethnic group. There have been many reports on 
the genetic polymorphisms of CYP2C. Some studies have reported 
that the hydroxylation metabolism of S-mephenytoin showed 
genetic polymorphism.53,54 It was also determined that this enzyme 
catalyzes the metabolism of some drugs such as S-mephenytoin, 
methylphenobarbital, omeprazole, phenytoin, imipramine, 
proguanil, propranolol and diazepam.55 It has also reported that 
CYP2C shows a possible clinical role in determining interindividual 
and interethnic differences in drug effectiveness. 
Change in CYP expression can affect drug response and activity. 
The ethnic differences in the frequency of CYP2C19 mutant alleles 
continues to be a significant study topic.56 In this current study, we 
assessed the distribution of CYP2C19 variants in the Turkman 
ethnic group and compared the data with those from other 
populations. The CYP2C19*2 variant was the most allele among 
Turkman ethnic groups. The frequency of this variant was 23.57% in 
the present study. Its frequency was lower than the figures reported 
from Chinese (45.5%),27 Japanese (27.4%),28 Thai (29%),30 Karen 
(28%),30 Malaysians (28%),31 Filipino (29%),32 Vanuatu and other 
Pacific islands (63.3%),51 as well as Australian Aborigines (35.5%).52 
The frequency of CYP2C19*2 has been reported to range  from 
20.9% to 45.5%, 12%-15%, 35.5%-63.3%, 9.1%-15.9%, 13%-19.1%, 
7.8%, 14%-18.8%, 10.9%-19% and 13%-14% in East Asian,27-32 
West Asian,32-34 Oceanian,51,52 European,33,38,39 North American 
and Canadian,32,40 South American (Bolivian),41 Scandinavian,42-44 
African38,45-50 and Iranian,25,26 respectively. The frequency of the 
CYP2C19*3 allele (20%) was high among the Turkman ethnic 
group when compared with some East and West Asians,27,31-34 
Oceanian,51,52 European,33,38,39 North American and Canadian,32,40 
South American (Bolivian),41 Scandinavian,42-44 African38,45-50 and 
Iranian25,26 populations, respectively. All combinations of alleles 
are shown in Tables 4 and 5. These results appear to suggest that 
CYP2C19*2 and CYP2C19*3 mutations are distinctive in different 
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Table 4: Comparison of allele frequencies of CYP2C19 of the Turkman ethnic group with different populations.
Population study Sample size
Allele frequency % (p-value versus Turkman ethnic group)
1 2 3
Iran
Turkman
Iranian(Tehran)25
Iranian (Southern)26
140
200
150
56.43
86
86.73
23.57
14(0.04)
13(0.001)
20
0(<0.001)
1(<0.001)
East Asia
Chinese27
Japanese28
Koreans29
Thai30
Burmese30
Karen30
Malaysians31
Filipino32
121
217
103
774
127
131
142
52
50
61.8
67.5
68
66
71
66
54
45.5 (<0.001)
27.4(NS)
20.9(NS)
29(NS)
30(NS)
28(NS)
28(NS)
39(0.040)
4.5(0.005)
10.8(0.013)
11.7(NS)
3(<0.001)
4(<0.001)
1(<0.001)
6(<0.001)
8(0.042)
West Asia
Turkish33
Jewish Israel34
Saudi Arabia32
404
140
97
87
84
85
12(0.001)
15(NS)
15(NS)
0.4 (<0.001)
1(<0.001)
0(<0.001)
Europe
Russians35
Italians36
Croatians37
Belgian38
Germans33
Portuguese39
290
360
200
121
328
153
88
88.9
85
90
84
87
11.4 (0.001)
11.1 (0.001)
15 (0.045)
9.1 (0.001)
15.9 (0.047)
13 (0.001)
0.3 (<0.001)
0 (<0.001)
0 (<0.001)
0 (<0.001)
0.2 (<0.001)
0 (<0.001)
North America and Canada
Canadian Native Indian40
Americans32
115
105
80.9
87
19.1(NS)
13(0.044)
0 (<0.001)
0 (<0.001)
South America
Bolivian41 778 92.1 7.8(0.001) 0.1 (<0.001)
Scandinavia
Faroese42
Swedish43
Danish44
310
83
239
81.8
85
84
18.8(NS)
14(NS)
16(NS)
0 (<0.001)
0.1 (<0.001)
0 (<0.001)
Africa
African Americans45
Egyptians46
Ethiopians47
Tansanians48
Zimbabweans49
Venda50
Beninese38
517
247
114
251
84
76
111
81
88.8
85
81
87
78.3
87
19(NS)
10.9(0.001)
14(NS)
18(NS)
13(NS)
21.7(NS)
13(0.027)
0 (<0.001)
0.2 (<0.001)
3 (<0.001)
1 (<0.001)
0 (<0.001)
0 (<0.001)
0 (<0.001)
Oceania
Vanuatu and other Pacific 
islands51
Australian aborigines52
5538
227
22.3
50.1
63.3 (0.001)
35.5 (0.015)
14.4(NS)
14.3(NS)
Differences in the allele frequencies were determined by Fisher exact test. NS: No significant differences.
ethnic groups. Some studies have shown that the CYP2C19*2 and 
CYP2C19*3 mutant alleles are collaborated with reduced enzyme 
activity. Clinical studies have shown that patients with CYP2C19*2 
allele showed lower levels of the metabolite's activities. This causes 
a decrease in platelet inhibition activity and higher rates of cardiac 
occurrences.57 According to various studies, the functional loss of 
CYP2C19 allelic variants is not in favor of cardiovascular systems 
following clopidogrel therapeutical regiment.58-60 
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Table 5: Comparison of CYP2C19 genotype and poor metabolizer frequency between Turkman ethnic group and other populations.
Study groups Sample size
Genotype frequency % (p-value versus Turkman ethnic 
group) PM genotype (%)
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3
Iran
Turkman 140 37.9 42.1 9.3 9.3 0 1.4 10
East Asia
Chinese27
Japanese28
Koreans29
Thai30
Burmese30
Karen30
Malaysians31
Filipino32
121
217
103
774
127
131
142
104
-
-
-
44.5
44.1
51.1
42
-
-
-
-
42.6
39.4
39.7
40
-
-
-
-
3.7
5.5
0.8
6
-
-
-
-
6.7
9.4
7.6
6
-
-
-
-
2.1
1.6
0.8
6.3
-
-
-
-
0.4
0
0
1
-
24 (0.002)
15.2 (NS)
11.7(NS)
9.2(NS)
11(NS)
8.4(NS)
12.7(NS)
25(NS)
West Asia
Turkish33
Jewish Israel34
Saudi Arabia32
404
140
97
76
70.7
-
22.3
26.4
-
0.74
1.4
-
0.9
2
-
0
0
-
0
0
-
1(<0.001)
2.8(0.015)
2(0.017)
Oceania
Vanuatu and other Pacific islands51
Australian aborigines52
5,538
227
-
-
-
-
-
-
-
-
-
-
-
-
61(<0.001)
25.6(<0.001)
Europe
Russians35
Italians36
Croatians37
Belgian38
Germans33
Portuguese39
290
360
200
121
328
153
78.7
79.4
73
83.5
-
-
19
18.9
24
15
-
-
0.3
0
0
0
-
-
1.7
1.7
3
1.6
-
-
0.3
0
0
0
-
-
0
0
0
0
-
-
2(<0.001)
1.7(<0.001)
3(<0.001)
1.6(0.005)
4.3(0.017)
1(NS)
North America and Canada
Canadian Native40 Indian32
Americans
115
105
-
-
-
-
-
-
-
-
-
-
-
-
7(NS)
2(0.011)
South America
Bolinian41 778 85.3 13.5 0.1 1 0 0 1(0.001)
Faroese42
Swedish43
Danish44
310
83
239
66.2
71
71.5
31.2
27
24.7
0
1
0
3.2
1
3.8
0
0
0
0
0
0
3.2(0.003)
1.2(0.011)
3.8(0.014)
Africa
AfricansAmericans45
Egiptians46
Ethiopians47
Tanzanians48
Zimbabweans49
Venda50
Beninese38
517
247
114
251
84
76
111
66
78.6
75
66
77
61.8
74
30
20.2
19
30
19
32.9
26.1
0
0.4
1
1
0
0
0
3
0.8
3
3
4
5.3
0
0.1
0
3
0
0
0
0
0
0
0
0
0
0
0
3.7(0.002)
0.8(0.001)
5.3(NS)
3.2(0.005)
3.6(NS)
7(NS)
0 (<0.001)
Differences in the allele frequencies were determined by Fisher exact test. NS: No significant differences.
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In a separate study, it was shown that CYP2C19 allelic variants 
functional loss did not have any adverse effect on the safety 
and efficacy of clopidogrel among patients with acute coronary 
diseases.61 Comparison of the Turkman ethnic group with other 
ethnic populations indicates differences and resemblances in 
the distribution of CYP2C19 allele and PM genotype. The 
differences may be associated with racial origin, geographical 
distribution and environmental factors, etc. Differences in the 
frequency of CYP2C19 polymorphism in different populations 
have epidemiologic importance. The frequency of CYP2C19*2 is 
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reported to be around 10% worldwide. Studies have shown that 
the frequency of CYP2C19*2 generally increases sequentially from 
Western Asia, Iran to India and Melanesian (with higher than 75% 
rate). On the other hand, CYP2C19*3 frequency exhibits the same 
direction. The increase begins in Eastern Asia with the highest 
prevalency in Melanesia with 33%, but it has been obeserved that its 
frequency in other part of the world is very low (lower and/or equal 
to 1%). The frequency of CYP2C19 variant can be as high as 90% 
in other regions of the world.62 
CYP2C19 polymorphism is related to metabolism of some 
important drugs.55,56 CYP 2C19 phenotypes are reported to 
affect clinical benefit of several drugs, such as proton pump 
inhibitors, clopitogrel, sertraline, escitalopram, moclobemide and 
voriconazol.63 Gastric acid-related abnormalities can be treated 
with the drug inhibitors and the proton pump inhibitors are 
sequentially metabolized by CYP2C19 in the liver. CYP2C19 from 
different genetic backgrounds metabolize the above mentioned drug 
differently and studies have shown that Japanese and Caucasians poor 
metabolizers respond properly to the drug with therapeutic dosage, 
but extensive metabolizers have been shown to have no effect on the 
above drug at therapeutic dosage.64-66 In a recent clinical trial study, 
the advantage of CYP2C19 genotype sub-population in having a 
good response to the proton pump inhibitor in therapeutic dosage 
was confirmed.67 The finding from another study indicated that 
Asian populations represent slower metabolism of diazepam than 
Caucasians. This may depend on the high frequency of the mutant 
CYP2C19*2 and CYP2C19*3 alleles in Asian populations.56 Toxic 
doses of diazepam may arise as the result of slower metabolism in 
PMs. Thus, extra care must be taken with the dosage of diazepam 
in Asian populations. Subjects with the variants CYP2C19*2 or 
CYP2C19*3 can denomstrate abnormality in metabolism for drugs 
such as diazepam, with adverse drug reactions. 
The present study showed that PM genotype frequency was 
highly (10.7%) expressed among the Turkman ethnic group when 
compared with West Asian,32-34 Europeans,33,35-39 North and South 
Americans,32,40,41 as well as Scandinavians,42-44 and Africans.45-49 
While PM genotype frequency in the Turkman ethnic group was 
lower than some East Asian27-32 and Oceanian51,52 populations. 
Moreover, our study showed that the frequency of poor metabolizers 
in the Turkman ethnic group (10.7%) is relatively close to Thai 
(9.2%) and Burmese (11%) populations.30 
Conclusion
This study confirms the ethnic differences in the CYP2C19 allele and 
genotype frequencies. Our results also showed that the determined 
allelic variants of CYP2C19 (CYP2C19*2 and CYP2C19*3 
mutations) in the Turkman ethnic group are comparable to other 
populations. Overall, the determination of CYP2C19 variants in 
different ethnic groups can be very useful for clinicians to determine 
the optimal dosage and efficacy of drugs metabolized by this 
polymorphic enzyme.
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